Aprepitant in the Management of Biological Therapies-related Severe Pruritus

Phase 2 Completed 45 enrolled Campus-Bio-Medico University

Non-randomizedParallel-groupOpen-labelSupportive care

Summary

Itch is a common side effect of anti-epidermal growth factor receptor antibodies and tyrosine kinase inhibitors. Investigators designed a pilot single-center phase II study evaluating the effects of Aprepitant, a neurokinin receptor inhibitor, in managing biological therapy-induced pruritus.

Timeline

Start: 2010-09
Primary completion: 2011-11
Completion: 2011-11

Publications

Santini D, Vincenzi B, Guida FM, Imperatori M, Schiavon G, Venditti O, Frezza AM, Berti P, Tonini G. Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study. Lancet Oncol. 2012 Oct;13(10):1020-4. doi: 10.1016/S1470-2045(12)70373-X. Epub 2012 Sep 18.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Aprepitant	Other / unclassified	80 mg	—
Background	Fexofenadine	Unknown	—	—
Background	Prednisone	Other / unclassified	—	—

Indications

No indication recorded.